TRIM33 and dermatomyositis: Anti-TIF1γ detection in patients with a new diagnosis of DM ≥ 39 years of age may therefore prompt a thorough investigation for the detection of cancer and reduce cancer mortality rates, making the accurate detection of anti-TIF1γ a research priority.